



THOMSON MEDICAL GROUP LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration No. 199908381D)

APPLICATION FOR A FURTHER EXTENSION OF TIME FOR RESTORATION OF PUBLIC FLOAT

The Board of Directors (the “**Board**”) of Thomson Medical Group Limited (the “**Company**”) refers to the following announcements:

- (a) the announcement dated 12 September 2023 in relation to the loss of public float of the Company; and
- (b) the announcement dated 19 September 2023 in relation to the Singapore Exchange Securities Trading Limited’s (the “**SGX-ST**”) confirmation that it has no objection to granting the Company a period of 3 months until 10 December 2023 for the public float to be restored and to not suspend trading in the Company’s shares on the SGX-ST in the meantime.

The Board wishes to announce that it had applied to the SGX-ST for a further extension of time for the public float of the Company to be restored and to not suspend trading in the Company’s shares on the SGX-ST in the meantime.

The Board wishes to inform shareholders that the Company has today received a letter from the SGX-ST advising that it will grant the Company:

- (a) a further 1-month period till 10 January 2024 to explore options to restore the public float as required under Rule 723 of Listing Manual issued by the SGX-ST; and
- (b) the continued trading of the Company’s shares during this period.

The approval of the SGX-ST is subject to the Company monitoring the public float and trading activity in its shares on an ongoing basis, and making an immediate request for a trading halt if there is any indication of disorderly trading.

The Company will make such announcements as may be necessary and/or appropriate to update shareholders on the restoration of free float, including but not limited to the completion of the restoration of the free float and/or request for a trading halt in the event of any indication of disorderly trading.

The Board reiterates its advice to shareholders and investors to refrain from taking any action, which may be prejudicial to their interests, and to exercise caution when dealing in the securities of the Company. Shareholders and investors should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

By Order of the Board
THOMSON MEDICAL GROUP LIMITED

Dr Heng Jun Li Melvin
Executive Director and Group CEO
7 December 2023